Skip to main content

Already a subscriber? Make sure to log into your account before viewing this content. You can access your account by hitting the “login” button on the top right corner. Still unable to see the content after signing in? Make sure your card on file is up-to-date.

Pfizer has announced plans to continue developing a once-daily oral weight loss medication, joining the ranks of existing treatments such as Ozempic and Zepbound.

The pharmaceutical company revealed that clinical evaluations for danuglipron, an oral GLP-1 agonist candidate, have produced “encouraging” results, prompting further dose optimization studies. Pfizer had previously tested a twice-daily version of danuglipron but said they stopped developing it due to adverse effects like nausea and vomiting experienced by participants.

3888

Mikael Dolsten, Pfizer’s chief scientific officer, commented on the news, saying, “Obesity is a key therapeutic area for Pfizer, and the company has a robust pipeline of three clinical and several pre-clinical candidates. The most advanced of them, danuglipron, has demonstrated good efficacy in a twice-daily formulation, and we believe a once-daily formulation has the potential to have a competitive profile in the oral GLP-1 space.”

According to Pfizier, danuglipron aims to enhance insulin secretion and regulate blood sugar levels. Oral GLP-1 medications have been available since 2019, following the FDA’s approval of Rybelsus, a once-daily oral form of semaglutide, for managing type 2 diabetes alongside diet and exercise.

JOIN THE MOVEMENT

Keep up to date with our latest videos, news and content